

acta endocrino logica

Volume 85

May – August 1977

Copenhagen

CHIEF EDITOR J. STARUP . DENMARK

LOCAL EDITORS T. DECKERT . DENMARK

J.-F. DYMLING . SWEDEN

B.-A. LAMBERG . FINLAND

J. MÜLLER . SWITZERLAND

N. NORMAN . NORWAY

G. P. van REES . THE NETHERLANDS

J. TAMM . FEDERAL REPUBLIC OF GERMANY

CONSULTING EDITORS R. BORTH . CANADA

C. HAMBURGER . DENMARK

HYPOTHALAMUS

Aro A., Lamberg B.-A. & Pelkonen R.: Hypothalamic endocrine dysfunction in anorexia nervosa 673

Griffiths E. C., Jeffcoate S. L. & Holland D. T.: Inactivation of somatostatin by peptidases in different areas of the rat brain 1

Kalra P. S. & Kalra S. P.: Temporal changes in the hypothalamic and serum luteinizing hormone-releasing hormone (LH-RH) levels and the circulating ovarian steroids during the rat oestrous cycle 449

Orts R. J., Kocan K. M. & Johnson R. P.: Antifertility properties of bovine pineal extracts: reduction of ovulation and pre-ovulatory luteinizing hormone in the rat 225

PITUITARY

Alvarez E. O., Hancke J. L. & Advis J. P.: Indirect evidences of prolactin involvement in precocious puberty induced by hypothalamic lesions in female rats 11

Belforte L., Camanni F., Chiodini P. G., Liuzzi A., Massara F., Molinatti G. M., Müller E. E. & Silvestrini F.: Long-term treatment with 2-Br-a-ergocryptine in acromegaly 235

Ching M., Trakulrungsi C., Somana R., Evans A. B. & Evans E. S.: A re-assessment of the effect of thyrotrophin (TSH) on the tibial plate bioassay for growth hormone (GH) 25

Clemens J. A., Tinsley F. C. & Fuller R. W.: Evidence for a dopaminergic component in the series of neural events that lead to the pro-oestrous surge of LH 18

D'Agata R., Andó S., Gulizia S., Condorelli L., Paci C., Scapagnini U. & Polosa P.: The stimulation of prolactin secretion by sulpiride in "adolescent gynaecomastia" 692

Dickerman Z., Bar-Haim Y., Prager-Lewin R., Kaufman H. & Laron Z.: Plasma LH and FSH response to LRH and plasma testosterone levels in boys with irregular puberty 456

Döhler K.-D., von zur Mühlen A. & Döhler U.: Pituitary luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin from birth to puberty in female and male rats 718

Erhardt F. W. & Scriba P. C.: High molecular thyrotrophin ("big"-TSH) from human pituitaries: preparation and partial characterization 698

Fenske M. & Wuttke W.: Development of stress-induced pituitary prolactin and TSH release in male rats 729

Galton V. A.: Thyroid hormone-binding interactions in cytosol of rat anterior pituitary 256

Godden P. M. M., Luch M. R. & Scanes C. G.: The effect of luteinizing hormone-releasing hormone and steroids on the release of LH and FSH from incubated turkey pituitary cells 713

Gray A. B.: Analysis of diameters of human pituitary hormone secretory granules 249

<i>Gräf K.-J., Horowski R. & El Etreby M. F.</i> : Effect of prolactin inhibitory agents on the ectopic anterior pituitary and the mammary gland in rats	267
<i>ter Haar M. B. & MacKinnon P. C. B.</i> : Ovarian steroid effects on gonadotrophin output, and on the incorporation of ³⁵ S from methionine into protein of discrete brain areas and the anterior pituitary	279
<i>Knight P. J., Hamilton J. M. & Scanes C. G.</i> : Homologous radioimmunoassay for canine prolactin	736
<i>Lindholm J., Dige-Petersen H., Hummer L., Rasmussen P. & Korsgaard O.</i> : Effect of thyrotrophin releasing hormone (TRH) in patients with pituitary disorders	479
<i>Neureuther G., Schwandt P. & Otto J.</i> : Radioimmunoassay for porcine lipotrophic peptide B	291
<i>Strauch G., Lego A., Therain F. & Bricaire H.</i> : Reversible plasma and red blood cells volumes increases in acromegaly	465
<i>Vadstrup S.</i> : A comparison of the effect of TSH, GH and prolactin on the renal iodide excretion in unrestrained rabbits	488
<i>Vilhardt H., Baker R. V. & Hope D. B.</i> : Subcellular fractionation by centrifugation of homogenates of the neural lobe of the bovine pituitary gland; identification of different pools of hormone in the homogenate and isolation of neurosecretosomes	300
<i>Vogt J. H.</i> : Spontaneous regression of enlargement of the sella turcica and of associated panhypopituitary symptoms	684

THYROID

<i>Bastiani P. & Simon C.</i> : Long-term turnover of thyroid iodine in the rat as studied by the isotopic equilibrium method	357
<i>Brock Jacobsen B., Petersen B. & Andersen H.</i> : Changes in serum levels of thyroxine and thyroxine-binding proteins (TBG, TBPA, albumin) induced by venous stasis	39
<i>Frey H. M. M. & Haug E.</i> : Effect of prolonged oral administration of TRH on plasma levels of thyrotrophin and prolactin in normal individuals and in patients with primary hypothyroidism	744
<i>Gluzman B. E., Coleoni A. H., Targovnik H. M. & Niepomniszcz H.</i> : Effects of amiodarone on thyroid iodine metabolism in vitro	781
<i>Goldman M. & Bauer S. R.</i> : A comparative study of iodine uptake by thyroid and thymus glands of male and female Sprague-Dawley rats of different ages	64
<i>van Hardeveld C. & Kassenaar A. A. H.</i> : Influence of experimental hyperthyroidism on skeletal muscle metabolism in the rat	71
<i>Haug E., Frey H. M. M. & Sand T.</i> : The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease	335
<i>Himsworth R. L. & Kark A. E.</i> : Studies on a case of suppurative thyroiditis	55
<i>Kirkegaard C., Faber J., Friis T., Birk Lauridsen U., Rogowski P. & Siersbæk-Nielsen K.</i> : Intravenous and peroral TRH stimulation in sporadic atoxic goitre	508
<i>Langer P., Kokešová H., Michajlovskij N., Gschwendtová K., Hřčka R. & Bukovská M.</i> : Rapid disappearance of loading doses of thyroxine from blood and their excretion by the bile in rats	531
<i>Lemarchand-Béraud T., Holm A.-C. & Scazziga B. R.</i> : Triiodothyronine and thyroxine nuclear receptors in lymphocytes from normal, hyper- and hypothyroid subjects	44

<i>Maier R., Brugger M., Brückner H., Kamber B., Riniker B. & Rittel W.</i> : Analogues of human calcitonin	102
<i>Mosekilde L., Melsen F., Bagger J. P., Myhre-Jensen O. & Schwartz Sørensen N.</i> : Bone changes in hyperthyroidism: interrelationships between bone morphology, thyroid function and calcium-phosphorus metabolism	515
<i>Mulaisho C. & Utiger R. D.</i> : Serum thyroxine-binding globulin: determination by competitive ligand-binding assay in thyroid disease and pregnancy	314
<i>Nistrup Madsen S.</i> : Thyroid function and plasma cyclic AMP response to intravenous glucagon	760
<i>Ochi Y., Yoshimura M., Hachiya T. & Miyazaki T.</i> : Distribution of LATS activity in immunoglobulin G subclass	791
<i>Parker J. L. W., Ratcliffe J. G. & Alexander W. D.</i> : Sporadic non-toxic goitre	497
<i>Platzer S., Fill H., Riccabona G., Glatzl J., Seidl J., Cenderelli G., Migliardi M., Varetto H. & Costa A.</i> : Endemic goitre in Alto Adige (Italy)	325
<i>Triggs S. M. & Williams E. D.</i> : Experimental carcinogenesis in the rat thyroid follicular and C cells	84
<i>Valenta L. J., Strosberg A. D., Valenta V. & Jatón J.-C.</i> : Iodopeptides from human thyroglobulin	769
<i>Volpert E. M. & Prezyna A. P.</i> : Transplantable thyroid tumour in rats: iodine-amino acid distribution in successive tumour generations	93
<i>Wall J. R., Gray B. & Greenwood D. M.</i> : Total and "activated" peripheral blood T lymphocytes in patients with thyroid disorders	753
<i>Westgren U., Ahrén B., Burger A. & Melander A.</i> : Stimulation of peripheral T ₃ formation by oral but not by intravenous glucose administration in fasted subjects	526
<i>Westgren U., Melander A., Wåhlin E. & Lindgren J.</i> : Divergent effects of 6-propylthiouracil on 3,5,3'-triiodothyronine (T ₃) and 3,3',5'-triiodothyronine (RT ₃) serum levels in man	345
<i>Zaninovich A. A., Boado R., Degrossi O. & Matty A. J.</i> : In vivo studies on thyroxine and triiodothyronine metabolism in the rat	351

PARATHYROID

<i>Diétel M., Dorn G., Montz R. & Allenähr E.</i> : The effect of calcium and dibutyryl-cAMP on the secretion of parathyroid hormone by human parathyroid adenomas in organ culture	541
---	-----

MAMMARY GLANDS

<i>Peters J. M.</i> : The importance of insulin, cortisol, progesterone and prolactin for the mammatrophic effect of pregnant rat serum	548
---	-----

PANCREAS

<i>Claro A., Grill V., Efendić S. & Luft R.</i> : Studies on the mechanisms of somatostatin action on insulin release	379
<i>Edén S., Albertsson-Wikland K., Rosberg S. & Isaksson O.</i> : Effect of insulin and adrenaline on cyclic AMP in the diaphragm of normal and diabetic rats	806

<i>Efendić S., Lins P. E., Luft R., Sievertsson H. & Westin-Sjödahl G.:</i> Studies on the mechanism of somatostatin action on insulin release	579
<i>Eigenmann J. E., Becker M., Kammermann B., Leemann W., Heimann R., Zapf J. & Froesch E. R.:</i> Decrease of non-suppressible insulin-like activity after pancreatectomy and normalization by insulin therapy	818
<i>Eigenmann J. E., Francke-Müder M., Zapf J. & Froesch E. R.:</i> Non-suppressible insulin-like activity during acute metabolic and endocrine changes in dogs	571
<i>Enk B.:</i> Insulin secretion in insulin-requiring diabetics before and during insulin treatment	559
<i>Hanssen K. F. & Torjesen P. A.:</i> Increased serum prolactin in diabetic ketoacidosis; correlation between serum sodium and serum prolactin concentration	372
<i>Ludvigsson J. & Heding L. G.:</i> C-peptide in diabetic children after stimulation with glucagon compared with fasting C-peptide levels in non-diabetic children	364
<i>Trimble E. R., Buchanan K. D., Hadden D. R. & Montgomery D. A. D.:</i> Secretin: high plasma levels in diabetes mellitus	799

LIVER

<i>Seitz H. J., Krone W. & Tarnowski W.:</i> Physiological regulation of rat liver phosphoenolpyruvate carboxykinase (GTP) by insulin. Insignificance of a cyclic AMP-independent mechanism	389
---	-----

ADRENALS

<i>Fehér T., Bodrogi L., Fehér K. G., Poteczkin E. & Kölcsey I. S.:</i> Free and solvolyzable dehydroepiandrosterone and androsterone in blood of mammals under physiological conditions and following administration of dehydroepiandrosterone	126
<i>Hilfenhaus M.:</i> Urinary aldosterone excretion rate and plasma aldosterone concentration in the rat: effect of ACTH, DOC, furosemide and of changes in sodium balance	134
<i>Honn K V. & Chavin W.:</i> In vitro temporal cAMP and cortisol responses to ACTH by the normal human adrenal gland	823
<i>Kolanowski J., Esselinckx W., Nagant de Deuxchaisnes C. & Crabbé J.:</i> Adrenocortical response upon repeated stimulation with corticotrophin in patients lacking endogenous corticotrophin secretion	595
<i>Lombardi G., Oliver C., Lupoli G. & Minozzi M.:</i> Corticotrophic and melanotrophic functions in congenital adrenal hyperplasia	118
<i>Maschler I., Weidenfeld J., Müller A., Slavin S., Shaefer J., Chowers I. & Finkelstein M.:</i> A case of adrenogenital syndrome with aberrant 11 β -hydroxylation	832
<i>Nussdorfer G. G., Mazzocchi G., Robba C., Belloni A. S. & Rebuffat P.:</i> Effects of ACTH and dexamethasone on the zona glomerulosa of the rat adrenal cortex: an ultrastructural stereologic study	608
<i>Schöneshöfer M., L'age M. & Oelkers W.:</i> Short time kinetics of deoxycorticosterone, deoxycortisol, corticosterone and cortisol during single dose metyrapone test	109
<i>Yamamoto S., Utsu S., Tanioka Y & Ohsawa N.:</i> Extremely high levels of corticosteroids and low levels of corticosteroid binding macromolecules in plasma of marmoset monkeys	398

<i>Ølgaard K., Hagen C., Madsen S. & Hummer L.:</i> Lack of effect of prolactin inhibition by alpha-bromergocriptine (CB 154) on plasma aldosterone in anephric and non-nephrectomized patients on regular haemodialysis	587
--	-----

OVARIES

<i>Aono T., Miyazaki M., Miyake A., Kinugasa T., Kurachi K. & Matsumoto K.:</i> Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries	840
<i>Davy M., Torjesen P. A. & Aakvaag A.:</i> Demonstration of an FSH receptor in a functioning granulosa cell tumour	615
<i>Isaacs A. J. & Havad C. W. H.:</i> Effect of piperazine oestrone sulphate on serum lipids and lipoproteins in menopausal women	143
<i>Pittaway D E., Andersen R. N. & Givens J. R.:</i> Characterization of human ovarian oestradiol-17 β oxidoreductase activity	624
<i>Plus-Roser S., Hassani M. & Aron C.:</i> The role of follicle-stimulating hormone (FSH) in combination with luteinizing hormone (LH), in oestrogen-induced ovulation during the oestrous cycle in the rat	151
<i>Siebers J. W., Peters F. & Engel W.:</i> Ovarian HCG-binding capacity during the oestrous cycle of the rat	850
<i>Wagner W. C., Strohheln R. E. & Larson P. A.:</i> Effect of local or parenteral application of ACTH or hydrocortisone on bovine corpus luteum function	158

UTERUS

<i>Asai M.:</i> A new assay method for the determination of oestrogen receptors ..	855
<i>Hagenfeldt K., Landgren B.-M., Plantin L.-O. & Diczfalusy E.:</i> Trace elements in the human endometrium and decidua	406
<i>Jelínek J. & Jelínková M.:</i> Rat endometrium enzymes in 4-day oestrous cycle and early pregnancy	169

PREGNANCY

<i>Jeppsson S., Rannevik G. & Thorell J. I.:</i> Pituitary gonadotrophin secretion during the first weeks of pregnancy	177
<i>Svan H., Hall K., Ritzén M., Takano K. & Skottner A.:</i> Somatomedin A and B in serum from neonates, their mothers and cord blood	636
<i>Townsley J. D. & Pepe G. J.:</i> Serum dehydroepiandrosterone and dehydroepiandrosterone sulphate in baboon (<i>Papio papio</i>) pregnancy	415

TESTES

<i>Job J.-C., Gendrel D., Safar A., Roger M. & Chaussain J.-L.:</i> Pituitary LH and FSH and testosterone secretion in infants with undescended testes	644
--	-----

MISCELLANEOUS

<i>Adamopoulos D., Vlassopoulos C., Seitanides B., Contoyiannis P. & Vassilopoulos P.:</i> The relationship of sex steroids to uric acid levels in plasma and urine	198
<i>Bartsch W., Horst H.-J., Becker H. & Nehse G.:</i> Sex hormone binding globulin binding capacity, testosterone, 5 α -dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment	650
<i>Bolt H M., Bolt M. & Kappus H.:</i> Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man	189
<i>Kanke Y., Nishina H., Mori Y. & Bashey R. I.:</i> Study of the effect of oestradiol on hexosamine-containing substances and a possible receptor in the skin of male mice	429
<i>Kley H. K., Bartmann E. & Krüskemper H. L.:</i> A simple and rapid method to measure non-protein-bound fractions of cortisol, testosterone and oestradiol by equilibrium dialysis: comparison with centrifugal filtration	209
<i>Misra D, Gupta D. N. & Karkun J. N.:</i> Contribution of lactic acid by the ampullary and isthmic parts of rabbit Fallopian tube under altered hormonal conditions	665
<i>Trygstad O. & Foss I.:</i> Congenital generalized lipodystrophy and experimental lipotrophic diabetes in rabbits treated successfully with fenfluramine	436
<i>de Visser J & van der Vies J:</i> Oestrogenic activity of oestradiol-decanoate after oral administration to rodents	422
<i>Wahlberg P., Carlsson E. & Brandt U.:</i> Lack of acute effect of triiodothyronine on noradrenaline responses of isolated sympathectomized cat hearts	220

- Aakvaag A., 615
 Adamopoulos D., 198
 Advis J. P., 11
 Ahrén B., 526
 Albertsson-Wikland K., 806
 Alexander W. D., 497
 Altenähr E., 541
 Alvarez E. O., 11
 Andersen H., 39
 Andersen R. N., 624
 Andó S., 692
 Aono T., 840
 Aro A., 673
 Aron C., 151
 Asai M., 855
- Bagger J. P., 515
 Baker R. V., 300
 Bar-Haim Y., 456
 Bartmann E., 209
 Bartsch W., 650
 Bashey R. I., 429
 Bastiani P., 357
 Bauer S. R., 64
 Becker H., 650
 Becker M., 818
 Belforte L., 235
 Belloni A. S., 608
 Birk Lauridsen U., 508
 Boado R., 351
 Bodrogi L., 126
 Bolt H. M., 189
 Bolt M., 189
 Brandt U., 220
 Bricaire H., 465
 Brock Jacobsen B., 39
 Brugger M., 102
 Brückner H., 102
 Buchanan K. D., 799
 Bukovská M., 531
 Burger A., 526
- Camanni F., 235
 Carlsson E., 220
- Cenderelli G., 325
 Chavin W., 823
 Ching M., 25
 Chiodini P. G., 235
 Chaussain J.-L., 644
 Chowers I., 832
 Claro A., 379
 Clemens J. A., 18
 Coleoni A. H., 781
 Condorelli L., 692
 Contoyiannis P., 198
 Costa A., 325
 Crabbé J., 595
- D'Agata R., 692
 Davy M., 615
 Degrossi O., 351
 Dickerman Z., 456
 Diczfalusy E., 406
 Dietel M., 541
 Dige-Petersen H., 479
 Dorn G., 541
 Döhler K.-D., 718
 Döhler U., 718
- Edén S., 806
 Edendié S., 379, 818
 Eigenmann J. E., 571, 818
 El Etreby M. F., 267
 Engel W., 850
 Enk B., 559
 Erhardt F. W., 698
 Essclinckx W., 595
 Evans A. B., 25
 Evans E. S., 25
- Faber J., 508
 Fehér K. G., 126
 Fehér T., 126
 Fenske M., 729
 Fill H., 325
 Finkelstein M., 332
 Foss I., 436
 Francke-Mäder M., 571

- Frey H. M. M., 335, 744
 Friis T., 508
 Froesch E. R., 571, 818
 Fuller R. W., 18

 Galton V. A., 256
 Gendrel D., 644
 Givens J. R., 624
 Glatzl J., 325
 Gluzman B. E., 781
 Godden P. M. M., 713
 Goldman M., 64
 Gray A. B., 249
 Gray B., 753
 Greenwood D. M., 753
 Griffiths E. C., 1
 Grill V., 379
 Gräf K.-J., 267
 Gschwendtová K., 531
 Gulizia S., 692
 Gupta D. N., 665

 ter Haar M. B., 279
 Hachiya T., 791
 Hadden D. R., 799
 Hagen C., 587
 Hagenfeldt K., 406
 Hall K., 636
 Hamilton J. M., 736
 Hancke J. L., 11
 Hanssen K. F., 372
 van Hardeveld C., 71
 Hassani M., 151
 Haug E., 335, 744
 Havard C. W. H., 143
 Heding L. G., 364
 Heimann R., 818
 Hilfenhaus M., 134
 Himsworth R. L., 55
 Holland D. T., 1
 Holm A.-C., 44
 Honn K. V., 823
 Hope D. B., 300
 Horowski R., 267
 Horst H.-J., 650
 Hrčka R., 531
 Hummer L., 479, 587

 Isaacs A. J., 143
 Isaksson O., 806

 Jacobsen B. B., 39
 Jatón J.-C., 769
 Jeffcoate S. L., 1
 Jelínek J., 169
 Jelínková M., 169
 Jeppsson S., 177
 Job J.-C., 644
 Johnson R. P., 225

 Kalra P. S., 449
 Kalra S. P., 449
 Kamber B., 102
 Kammermann B., 818
 Kanke Y., 429
 Kappus H., 189
 Kark A. E., 55
 Karkun J. N., 665
 Kassenaar A. A. H., 71
 Kaufman H., 456
 Kinugasa T., 840
 Kirkegaard C., 508
 Kley H. K., 209
 Knight P. J., 736
 Kokan K. M., 225
 Kokešová H., 531
 Kolanowski J., 595
 Korsgaard O., 479
 Krone W., 389
 Krüskemper H. L., 209
 Kurachi K., 840
 Kölcsey I. S., 126

 L'age M., 109
 Lambert B.-A., 673
 Landgren B.-M., 406
 Langer P., 531
 Laron Z., 456
 Larson P. A., 158
 Lauridsen U. B., 508
 Leemann W., 818
 Lego A., 465
 Lemarchand-Béraud T., 44
 Lindgren J., 345
 Lindholm J., 479
 Lins P. E., 579
 Liuzzi A., 235
 Lombardi G., 118
 Luck M. R., 713
 Ludvigsson J., 364
 Luft R., 379, 579
 Lupoli G., 118

- MacKinnon P. C. B., 279
 Madsen S., 587
 Madsen S. N., 760
 Maier R., 102
 Maschler I., 832
 Massara F., 235
 Matsumoto K., 840
 Matty A. J., 351
 Mazzocchi G., 608
 Melander A., 345, 526
 Melsen F., 515
 Michajlovskij N., 531
 Migliardi M., 325
 Minozzi M., 118
 Misra D., 665
 Miyaka A., 840
 Miyazaki M., 840
 Miyazaki T., 791
 Molinatti G. M., 235
 Montgomery D. A. D., 799
 Montz R., 541
 Mori Y., 429
 Mosekilde L., 515
 Mulaisho C., 314
 Muller A., 832
 von zur Mühlen A., 718
 Müller E. E., 235
 Myhre-Jensen O., 515
- Nagant de Deuxchaisnes C., 595
 Nehse G., 650
 Neureuther G., 291
 Niepomniszcze H., 781
 Nishina H., 429
 Nistrup Madsen S., 760
 Nussdorfer G. G., 608
- Ochi Y., 791
 Oelkers W., 109
 Ohsawa N., 398
 Oliver C., 118
 Orts R. J., 225
 Otto J., 291
- Paci C., 692
 Parker J. L. W., 497
 Pelkonen R., 673
 Pepe G. J., 415
 Peters F., 850
- Peters J. M., 548
 Petersen B., 39
 Pittaway D. E., 624
 Plantin L.-O., 406
 Plas-Roser S., 151
 Platzer S., 325
 Polosa P., 692
 Poteczin E., 126
 Prager-Lewin R., 456
 Prezyna A. P., 93
- Rannevik G., 177
 Rasmussen P., 479
 Ratcliffe J. G., 497
 Rebuffat P., 608
 Riccabona G., 325
 Riniker B., 102
 Rittel W., 102
 Ritzén M., 636
 Robba C., 608
 Roger M., 644
 Rogowski P., 508
 Rosberg S., 806
- Safar A., 644
 Sand T., 335
 Scanes C. G., 713, 736
 Scapagnini U., 692
 Scazziga B. R., 44
 Schwandt P., 291
 Schwartz Sørensen N., 515
 Schöneshöfer M., 109
 Scriba P. C., 698
 Seidl J., 325
 Seitanides B., 198
 Seitz H. J., 389
 Shaefer J., 832
 Siebers J. W., 850
 Siersbæk-Nielsen K., 508
 Sievertsson H., 579
 Silvestrini F., 235
 Simon C., 357
 Skottner A., 636
 Slavin S., 832
 Somana R., 25
 Strauch G., 465
 Strohhahn R. E., 158
 Strosberg A. D., 769
 Svan H., 636
 Sørensen N. S., 515

Takano K., 636
Tanioka Y., 398
Targovnik H. M., 781
Tarnowski W., 389
Therain F., 465
Thorell J. I., 177
Tinsley F. C., 18
Torjesen P. A., 372, 615
Townsend J. D., 415
Trakulrunsi C., 25
Triggs S. M., 84
Trimble E. R., 799
Trygstad O., 436

Utiger R. D., 314
Utsu S., 398

Vadstrup S., 488
Valenta L. J., 769
Valenta V., 769
Varetto H., 325
Vassilopoulos P., 198
van der Vies J., 422
Vilhardt H., 300

de Visser J., 422
Vlassopoulos C., 198
Vogt J. H., 684
Volpert E. M., 93

Wagner W. C., 158
Wahlberg P., 220
Wall J. R., 753
Weidenfeld J., 832
Westin-Sjödahl G., 579
Westgren U., 345, 526
Williams E. D., 84
Wuttke W., 729
Wählin E., 345

Yamamoto S., 398
Yoshimura M., 791

Zaninovich A. A., 351
Zapf J., 571, 818

Ølgaard K., 587

ACROMEGALY

- effects of thyrotrophin releasing hormone in patients with hypophyseal disorders, 479
- long-term treatment with 2-bromo- α -ergocryptine, 235
- reversible plasma and red blood cells volumes increases, 465

ADAPTATION SYNDROME

- stress-induced release of prolactin and TSH in rats, 729

"ADOLESCENT GYNAECOMASTIA"

- stimulation of prolactin secretion by sulpiride, 692

ADRENAL CORTEX

- adrenogenital syndrome with aberrant 11β -hydroxylation, 832
- congenital adrenal hyperplasia; corticotrophic and melanotrophic functions, 118
- in vitro* temporal cyclic AMP and cortisol responses to ACTH by normal human adrenals, 823
- pituitary-adrenal function in anorexia nervosa, 673
- response to repeated ACTH stimulation in patients lacking endogenous ACTH secretion, 595
- zona glomerulosa; structural changes after long-term administration of ACTH and dexamethasone, 608

ADRENALINE

- effect of insulin and adrenaline on cyclic AMP in diaphragm of normal and diabetic rats, 806

ALBUMIN

- serum levels in man; changes induced by venous stasis, 39

ALDOSTERONE

- excretion rate and plasma concentration in the rat; effects of ACTH, DOC, furosemide and changes in sodium balance, 134
- plasma aldosterone in anephric and non-nephrectomized patients on haemodialysis; lack of effect of prolactin inhibition, 587

AMIODARONE

- effect on thyroid iodine metabolism *in vitro*, 781

AMP

- effect of adrenaline and insulin on cyclic AMP in diaphragm of normal and diabetic rats, 806
- effect of dibutyl-cyclic AMP on secretion of parathyroid hormone by human parathyroid adenomas in organ culture, 541
- effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets, 379
- in vitro* temporal cyclic AMP response to ACTH by normal human adrenals, 823
- plasma cyclic AMP response to intravenous glucagon, 760

ANDROGENS

- free and solvolysable DHEA and A in blood of mammals under physiological conditions and following DHEA, 126
- serum DHEA and DHEA sulphate in baboon (*Papio papio*) pregnancy, 415

ANDROSTERONE

- free and solvolysable DHEA and A in blood of mammals under physiological conditions and following DHEA, 126

ANOREXIA NERVOSA

hypothalamic endocrine dysfunction, 673

ANTIFERTILITY

reduction of ovulation and pre-ovulatory LH in the rat by bovine pineal extracts, 225

ANTITHYROID COMPOUNDS

6-propylthiouracil; divergent effects on T_3 and RT_3 serum levels in man, 345

BLOOD

reversible plasma and erythrocyte volumes increases in acromegaly, 465

BONE

bone changes in hyperthyroidism; inter-relationships between bone morphology, thyroid function and calcium-phosphorus metabolism, 515

BRAIN

incorporation of ^{35}S from methionine into protein of discrete brain areas in rats, 279

peptidases in hypothalamus and other areas of the rat brain; inactivation of somatostatin, 1

2-BROMO- α -ERGOCRYPTINE

effects on precocious puberty induced by hypothalamic lesions, 11
effects on the ectopic adenohypophysis and the mammary gland in rats, 267
long-term treatment in acromegaly, 235

prolactin inhibition by 2-bromo- α -ergocryptine; lack of effect on plasma aldosterone in anephric and non-nephrectomized patients in haemodialysis, 587

2-BUTYL,3-(4-DIETHYLAMINO-ETHOXY)-3,5-DIODO, BENZOYL) BENZOFURAN see AMIODARONE

CALCITONIN

analogues of human calcitonin; influence of basic amino acids on hypocalcaemic activity in the rat, 102

CALCIUM

calcium-phosphorus metabolism in hyperthyroidism, 515
effect of calcium and dibutyl-cyclic AMP on secretion of parathyroid hormone by human parathyroid adenomas in organ culture, 541
effect of dietary Ca on experimental carcinogenesis in the rat thyroid follicles and C cells, 84
hypocalcaemic activity of human calcitonin analogues, 102

CARCINOGENESIS

effect of dietary Ca and radiation on experimental carcinogenesis in the rat thyroid follicles and C cells, 84

CARTILAGE

effect of thyrotrophin on the tibial plate bioassay for growth hormone, 25

CHORIONIC GONADOTROPHIN

ovarian HCG-binding capacity during the oestrous cycle of the rat, 850
plasma concentration during the first weeks of human pregnancy, 177

CHROMATIN

a new method for determination of oestrogen receptors, 855

COMPETITIVE LIGAND-BINDING ASSAY

of serum thyroxine-binding globulin, 314

CONGENITAL ADRENAL HYPERPLASIA

corticotrophic and melanotrophic functions, 118

CONGENITAL GENERALIZED LIPODYSTROPHY

successful treatment with fenfluramine, 436

CONNECTIVE TISSUES

effect of oestradiol on hexosamine-containing substances and a possible receptor in the skin of male mice, 429

CORPUS LUTEUM

effect of local and parenteral application of ACTH or cortisol on bovine corpus luteum function, 158

CORTICOSTEROIDS

dexamethasone; effect of long-term administration on structure of rat zona glomerulosa, 608
high levels of corticosteroids and low levels of corticosteroid-binding macromolecule in plasma of marmoset monkeys, 398
long-term corticosteroid therapy; adrenocortical response to ACTH, 595
short-time kinetics of deoxycorticosterone, deoxycortisol, corticosterone and cortisol during single dose metyrapone test, 109

CORTICOSTERONE

short-time kinetics during single dose metyrapone test, 109

CORTICOTROPHIN

adrenocortical response to repeated ACTH stimulation in patients lacking endogenous ACTH secretion, 595
corticotrophic function in congenital adrenal hyperplasia, 118
effect of local or parenteral application on bovine corpus luteum function, 158
effect of long-term administration on structure of rat zona glomerulosa, 608
effect on aldosterone excretion rate and plasma aldosterone in the rat, 134
effect on corticosteroids in plasma of marmoset monkeys, 398
in vitro temporal cyclic AMP and cortisol response to ACTH by normal human adrenals, 823

CORTISOL

assay of non-protein-bound cortisol by equilibrium dialysis, 209

effect of local or parenteral application on bovine corpus luteum function, 158

importance for the mammatrophic effect of pregnant rats' serum, 548
in vitro temporal cortisol response to ACTH by normal human adrenals, 823
short-time kinetics during single dose metyrapone test, 109

CORTISONE

short-time kinetics during single dose metyrapone test, 109

CRYPTORCHIDISM

in infants; testosterone secretion and LH and FSH response to LH-RH, 644

DEHYDROEPIANDROSTERONE

free and solvolysable DHEA and A in blood of mammals under physiological conditions and following DHEA, 126
serum DHEA and DHEA sulphate in baboon (*Papio papio*) pregnancy, 415

DEOXYCORTICOSTERONE

effect on aldosterone excretion rate and plasma aldosterone in the rat, 134
short-time kinetics during single dose metyrapone test, 109

DEOXYCORTISOL

short-time kinetics during single dose metyrapone test, 109

DEXAMETHASONE

effect of long-term administration on structure of rat zona glomerulosa, 608

DIABETES MELLITUS

diabetic ketoacidosis; increased serum prolactin levels; correlation with serum sodium, 372
effect of insulin and adrenaline on cyclic AMP in the diaphragm of diabetic rats, 806

- insulin secretion in insulin-requiring diabetics before and during insulin treatment, 559
- C-peptide and total IRI in diabetic children after administration of glucagon; comparison with non-diabetic children, 364
- secretion; high levels in diabetes mellitus, 799
- DIHYDROPROGESTERONE**
effect on incorporation of ^{35}S from methionine into proteins from brain and hypophysis in rats, 279
effect on pro-oestrous LH surge in rats, 279
- 5 α -DIHYDROTESTOSTERONE**
in plasma of patients with prostatic carcinoma under hormonal treatment, 650
- DOPAMINE**
participation in the neural events leading to the pro-oestrous surge of LH, 18
- ENDOMETRIUM**
trace elements in the human endometrium, 406
- ENZYMES**
characterization of human oestradiol-17 β oxidoreductase activity, 624
11 β -hydroxylation; aberrant activity in a case of adrenogenital syndrome, 832
peptidase in hypothalamus and other areas of the rat brain; inactivation of somatostatin, 1
phosphodiesterase activity in isolated rat pancreatic islets; effect of somatostatin, 379
phosphoenolpyruvate carboxykinase in rat liver; physiological regulation, 389
rat endometrium enzymes in 4-day oestrous cycle and early pregnancy, 169
- ERYTHROCYTES**
reversible volume increases in acromegaly, 465
- ETHINYLOESTRADIOL**
interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol, 189
- EQUILIBRIUM DIALYSIS**
assay of non-protein-bound cortisol, testosterone and oestradiol; comparison with centrifugal filtration, 209
- FALLOPIAN TUBE**
of rabbits; contribution of lactic acid under altered hormonal conditions, 665
- FASTING**
stimulation of peripheral T $_3$ formation by oral but not by iv glucose administration in fasted subjects, 526
- FENFLURAMINE**
congenital generalized lipodystrophy and experimental lipodystrophic diabetes in rabbits treated successfully with fenfluramine, 436
- FOLLICLE STIMULATING HORMONE**
FSH, LH and prolactin from birth to puberty in rats, 718
FSH receptor in a functioning granulosa cell tumour, 615
release of FSH and LH from incubated turkey pituitary cells, 713
response to LH-RH and oestrogens in Japanese women with polycystic ovaries, 840
response to LH-RH and plasma testosterone levels in boys with irregular puberty, 456
response to LH-RH in infants with undescended testes, 644.
role of FSH in combination with LH on oestrogen-induced ovulation in the rat, 151
secretion during the first weeks of human pregnancy, 177
- FUROSEMIDE**
effect on aldosterone excretion and plasma aldosterone in the rat, 134

GERONTOLOGY

iodine uptake by thyroid and thymus in rats of different ages, 64

GLOBULIN

distribution of LATS in immunoglobulin G subclass, 791
iodopeptides from human thyroglobulin, 769
sex hormone binding globulin in patients with prostatic carcinoma under hormonal treatment, 650
thyroxine-binding globulin; changes induced by venous stasis, 39
thyroxine-binding globulin; determination by competitive ligand-binding assay in thyroid diseases and in pregnancy, 314

GLUCAGON

C-peptide and total IRI in diabetic children after administration of glucagon, 364
thyroid function and plasma cyclic AMP response to intravenous glucagon, 760

GLUCOSE

stimulation of peripheral T₃ formation by oral but not by iv administration in fasted subjects, 526

GLYCOSAMINOGLYCANS

in the skin of male rats; effect of oestradiol, 429

GOITRE

endemic goitre in Alto Adige (Italy), 325
sporadic non-toxic goitre; a long-term follow-up of 36 patients, 497
sporadic non-toxic goitre; intravenous and peroral TRH stimulation, 508

GONADOTROPHINS

FSH, LH and prolactin from birth to puberty in rats, 718
hypophyseal gonadotrophins; secretion during the first weeks of human pregnancy, 177

LH and FSH response to LH-RH and plasma testosterone levels in boys with irregular puberty, 456
plasma gonadotrophins in a case of functioning granulosa cell tumour, 615
release from incubated turkey pituitary cells, 713
responses to LH-RH and oestrogens in Japanese woman with polycystic ovaries, 840
role of FSH and LH in oestrogen-induced ovulation in the rat, 151

GRANULOSA CELL TUMOUR

demonstration of an FSH receptor, 615
transplantation to nude mice; effects of gonadotrophins, 615

GROWTH HORMONE

assay; effect of thyrotrophin on the tibial plate bioassay, 25
comparison of the effects of GH, prolactin and TSH on renal iodide excretion in unrestrained rabbits, 488
hypothalamic endocrine dysfunction in anorexia nervosa, 673
lacking effect on NSILA-S in dogs, 571
plasma GH in acromegaly; suppression by 2-bromo- α -ergocryptine, 235

GYNAECOMASTIA

stimulation of prolactin secretion by sulphiride in "adolescent gynecomastia", 692

HAEMOCONCENTRATION

effect of venous stasis on serum levels of thyroxine-binding proteins in man, 39

HEXOSAMINE

effect of oestradiol on hexosamine-containing substances in the skin of male mice, 429

HIRSUTISM

a case of adrenogenital syndrome with aberrant 11 β -hydroxylation, 832

HUMAN CHORIONIC GONADOTROPHIN see CHORIONIC GONADOTROPHIN

11 β -HYDROXYLATION

aberrant activity in a case of adrenogenital syndrome, 832

HYPERTHYROIDISM

bone changes in hyperthyroidism, 515
experimental hyperthyroidism; effect on rat skeletal muscle metabolism, in particular lipolysis, 71

response of cyclic AMP to intravenous glucagon, 760

T₄ and T₃ nuclear receptors in lymphocytes from hyperthyroid subjects, 44

T₄-binding globulin concentration in serum in hyperthyroidism, 314

HYPOCALCAEMIA

hypocalcaemic activity of human calcitonin analogues, 102

HYPOPHYSIS (ANTERIOR LOBE)

cytosol fraction of rat pituitary cells; thyroid hormone-binding interactions, 256

ectopic adenohypophysis; effect of prolactin inhibitors in rats, 267
gonadotrophins; response to LH-RH and plasma testosterone levels in boys with irregular puberty, 456

gonadotrophins; response to LH-RH in infants with undescended testes, 644
gonadotrophins; secretion during the first weeks of human pregnancy, 177

high molecular thyrotrophin from human hypophyses, 698
incorporation of ³⁵S from methionine into rat hypophyseal protein; effects of ovarian steroids, 279

lipotropic peptide B; radioimmunoassay, 291

LH, FSH and prolactin from birth to puberty in rats, 718

LH pro-oestrous surge; dopaminergic component in the neural events leading to the surge in rats, 18
panhypopituitary symptoms; spontaneous regression of enlargement of the sella turcica, 684

pituitary-adrenal function in anorexia nervosa, 673

prolactin inhibitory agents, 267

prolactin involvement in precocious puberty induced by hypothalamic lesions in female rats, 11

release of LH and FSH from incubated turkey pituitary cells, 713

role of FSH and LH in oestrogen-induced ovulation in the rat, 151

secretory granules in man; analysis of diameters, 249

stress-induced release of prolactin and FSH in rats, 729

HYPOPHYSIS (POSTERIOR LOBE)

see NEUROHYPOPHYSIS

HYPOTHALAMUS

hypothalamic endocrine dysfunction in anorexia nervosa, 673

hypothalamic lesions inducing precocious puberty in female rats; prolactin involvement, 11

hypothalamic LH-RH; temporal changes during the rat oestrous cycle, 449

peptidases in rat hypothalamus; inactivation of somatostatin, 1

HYPOTHYROIDISM

effect of prolonged oral administration of TRH on plasma TSH and prolactin in normal subjects and in primary hypothyroidism, 744
response of cyclic AMP to intravenous glucagon, 760

T₄ and T₃ nuclear receptors in lymphocytes from hypothyroid subjects, 44

T₄-binding globulin concentration in serum in hypothyroidism, 314

IMMUNOGLOBULIN

distribution of LATS activity in immunoglobulin G subclass, 791

IMMUNOLOGY

homologous RIA for canine prolactin, 736

RIA for porcine lipotropic peptide B, 291

INSULIN

effect of insulin and adrenaline on cyclic AMP in diaphragm of normal and diabetic rats, 806

importance for the mammatrophic effect of pregnant rats' serum, 548

NSILA-S; decreased activity after pancreatectomy and normalization by insulin therapy, 818

NSILA-S during acute metabolic and endocrine changes in dogs, 571

physiological regulation of rat liver phosphoenolpyruvate carboxykinase by insulin, 389

release; mechanism of action of somatostatin, 379, 579

secretion in insulin-requiring diabetics before and during insulin treatment, 559

total immunoreactive insulin and C-peptide in diabetic children after administration of glucagon, 364

IODINE

iodeptides from human thyroglobulin, 769

long-term turnover of thyroid iodine as studied by the isotopic equilibrium method, 357

metabolism of thyroid iodine; effect of amiodarone, 781

renal iodide excretion in unrestrained rabbits; comparison of the effects of GH, prolactin and TSH, 488

uptake by thyroid and thymus in rats of different ages, 64

ISOTOPIC EQUILIBRIUM METHOD

studies on long-term turnover of thyroid iodine in the rat, 357

KETOACIDOSIS

increased serum prolactin in diabetic ketoacidosis; correlation with serum sodium, 372

KIDNEYS

lack of effect of prolactin inhibition on plasma aldosterone in anephric and non-nephrectomized patients on haemodialysis, 587

renal iodide excretion in unrestrained rabbits; comparison of the effects of GH, prolactin and TSH, 488

LACTATION

radioimmunoassay of prolactin in lactating dogs, 736

LACTIC ACID

contribution by the rat Fallopian tube under altered hormonal conditions, 665

LANGERHANS' ISLETS

effect of somatostatin analogues on arginine-induced release of insulin and glucagon from the perfused rat pancreas, 579

effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets, 379

LATS

distribution of LATS activity in immunoglobulin G subclass, 791

LERGOTRILE MESYLATE

effect on the pro-oestrous LH surge in rats, 18

LIPIDS

effect of piperazine oestrone sulphate on serum lipids in menopausal women, 143

LIPOATROPHIC DIABETES

in rabbits treated successfully with fenfluramine, 436

LIPOLYSIS

in rat skeletal muscles; effect of experimental hyperthyroidism, 71
radioimmunoassay for porcine lipotrophic peptide B, 291

LISURIDE HYDROGEN MALEATE

effect on the ectopic adenohypophysis and mammary glands in rats, 267

LIVER

physiological regulation of rat liver phosphoenolpyruvate carboxykinase, 389

LUTEINIZING HORMONE

- decreased response to LH-RH in infants with undescended testes, 644
- LH-RH; temporal changes during the rat oestrous cycle, 449
- pro-oestrous LH surge in rats; anti-fertility properties of bovine pineal extracts, 225
- pro-oestrous LH surge in rats; effects of lergotriple mesylate and reserpine, 18
- pro-oestrous LH surge in rats; effects of ovarian steroids, 279
- release of FSH and LH from incubated turkey pituitary cells, 713
- response to LH-RH and plasma testosterone levels in boys with irregular puberty, 456
- response to LH-RH in Japanese women with polycystic ovaries, 840
- role of FSH in combination with LH on oestrogen-induced ovulation in the rat, 151
- secretion during the first weeks of human pregnancy, 177
- serum levels in rats; effect of lergotriple mesylate and reserpine, 18

LYMPHOCYTES

- T₄ and T₈ nuclear receptors in lymphocytes from normal, hyper- and hypothyroid subjects, 44
- total and "activated" peripheral blood T lymphocytes in thyroid disorders, 753

MAMMARY GLANDS

- effect of prolactin inhibitors in rats, 267
- mammatrophic effect of pregnant rats' serum; importance of insulin, cortisol, prolactin and progesterone, 548

β -MELANOCYTE STIMULATING HORMONE

- function in congenital adrenal hyperplasia, 118

MENOPAUSE

- effect of piperazine oestrone sulphate on serum lipids and lipoproteins, 143

METYRAPONE

- short-time kinetics of deoxycorticosterone, deoxycortisol, corticosterone and cortisol during single dose metyrapone test, 109

MUSCLES

- effect of experimental hyperthyroidism on rat skeletal muscle metabolism, in particular lipolysis, 71

NEUROHYPOPHYSIS

- subcellular fractionation of homogenates of the bovine neurohypophysis; identification of hormones in the homogenate and isolation of neurosecretosomes, 300

NEUROSECRETOSOMES

- isolation from bovine neurohypophysis, 300

NORADRENALINE

- lack of acute effect of T₃ on noradrenaline response of isolated sympathectomized cat hearts, 220

OESTRADIOL

- assay of non-protein-bound oestradiol by equilibrium dialysis, 209
- effect on hexosamine-containing substances and possible receptor in the skin of male mice, 429
- effect on incorporation of ³⁵S from methionine into proteins of brain and hypophysis of rats, 279
- effect on pro-oestrous LH surge in rats, 279
- effect on release of LH and FSH from incubated turkey pituitary cells, 713
- oestradiol-decanoate; oestrogenic activity after oral administration to rodents, 422
- oestradiol-17 β oxidoreductase activity in human ovaries, 624
- plasma concentrations during the first weeks of human pregnancy, 177
- plasma concentration in a case of functioning granulosa cell tumour, 615

- plasma concentrations in patients with prostatic carcinoma under hormonal treatment, 650
- temporal changes in LH-RH and ovarian steroids during the rat oestrous cycle, 449
- OESTROGENS**
- effects on plasma and urinary uric acid in human subjects, 198
- ethinyloestradiol; interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol, 189
- oestrogenic activity of oestradiol-decanoate after oral administration to rodents, 422
- oestrogen receptors; a new assay method for determination, 855
- response of gonadotrophins to oestrogens and LH-RH in Japanese women with polycystic ovaries, 840
- OESTRONE**
- piperazine oestrone sulphate; effect on serum lipids and lipoproteins in menopausal women, 143
- OESTROUS CYCLE**
- ovarian HCG-binding capacity during the oestrous cycle of the rat, 850
- pro-oestrous LH surge in rats; dopaminergic component in neural events leading to the surge, 18
- rat endometrium enzymes in 4-day oestrous cycle and early pregnancy, 169
- temporal changes in hypothalamic and serum LH-RH and ovarian steroids during the rat oestrous cycle, 449
- OVARIES**
- bovine corpus luteum function; effect of local or parenteral application of ACTH and cortisol, 158
- characterization of human ovarian oestradiol-17 β oxidoreductase activity, 624
- functioning granulosa cell tumour; demonstration of an FSH receptor, 615
- ovarian HCG-binding capacity during the oestrous cycle of the rat, 850
- polycystic ovaries in Japanese women; gonadotrophin responses to LH-RH and oestrogens, 840
- OVIDUCT**
- contribution of lactic acid by the rabbit Fallopian tube under altered hormonal conditions, 665
- OVULATION**
- antifertility properties of bovine pineal extracts; reduction of ovulation in the rat, 225
- effects of lergotril mesylate and reserpine on ovulation in rats, 18
- oestrogen-induced ovulation in rats; role of FSH in combination with LH, 151
- OXIDOREDUCTASE**
- characterization of human ovarian oestradiol-17 β oxidoreductase activity, 624
- PAEDIATRICS**
- "adolescent gynaecomastia", 692
- boys with irregular puberty, 456
- PANCREAS**
- effect of somatostatin analogues on arginine-induced release of insulin and glucagon from the perfused rat pancreas, 579
- effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets, 379
- pancreatectomy; decrease of NSILA-S activity after the operation and normalization by insulin therapy, 818
- PANHYPOPITUITARISM**
- spontaneous regression of the symptoms, 684
- PARATHYROIDS**
- effects of Ca and dibutyryl-cyclic AMP on secretion of parathyroid hormone by human parathyroid adenomas in organ culture, 541

PEPTIDASES

in hypothalamus and other areas of the rat brain; inactivation of somatostatin, 1

PHOSPHODIESTERASE ACTIVITY

in isolated rat pancreatic islets; effect of somatostatin, 379

PHOSPHOENOLPYRUVATE

CARBOXYKINASE

physiological regulation in rat liver, 389

PHOSPHORUS

calcium-phosphorus metabolism in hyperthyroidism, 515

PINEAL BODY

antifertility properties of bovine pineal extracts; reduction of ovulation and pre-ovulatory LH in the rat, 225

PIPERAZINE OESTRONE

SULPHATE

effect on serum lipids and lipoproteins in menopausal women, 143

POLYCYSTIC OVARIES

responses of gonadotrophins to LH-RH and oestrogens in Japanese women with the syndrome, 840

PREGNANCY

antifertility properties of bovine pineal extracts in the rat, 225

hypophyseal gonadotrophins; secretion during the first weeks of human pregnancy, 177

mammotrophic effect of pregnant rats' serum, 548

radioimmunoassay of prolactin in pregnant dogs, 736

rat endometrium enzymes in early pregnancy, 169

serum DHEA and DHEA sulphate during pregnancy in the baboon (*Papio papio*), 415

serum T₄-binding globulin; determination in thyroid diseases and in pregnancy, 314

somatomedin A and B in serum from neonates, their mothers and cord blood, 636

trace elements in the human endometrium and decidua, 406

PREGNANEDIONE

effect on incorporation of ³⁵S from methionine into proteins of brain and hypophysis of rats, 279

effect on pro-oestrous LH surge in rats, 279

PROGESTERONE

effect on incorporation of ³⁵S from methionine into proteins of brain and hypophysis of rats, 279

effect on plasma and urinary uric acid in human subjects, 198

effect on pro-oestrous LH surge in rats, 279

effect on release of LH and FSH from incubated turkey pituitary cells, 713

importance for the mammatrophic effect of pregnant rats' serum, 548

plasma concentrations during the first weeks of human pregnancy, 177

temporal changes in LH-RH and ovarian steroids during the rat oestrous cycle, 449

PROLACTIN

comparison of the effects of prolactin, GH and TSH on renal iodide excretion in unrestrained rabbits, 488

homologous radioimmunoassay for canine prolactin, 736

importance for the mammatrophic effect of pregnant rats' serum, 548

increased serum prolactin in diabetic ketoacidosis; correlation with serum sodium, 372

involvement in precocious puberty induced by hypothalamic lesions in female rats, 11

plasma concentrations during the first weeks of human pregnancy, 177

plasma concentrations following prolonged TRH administration in normal subjects and in hypothyroidism, 744

- plasma concentrations in patients with prostatic carcinoma under hormonal treatment, 650
- prolactin inhibition by 2-bromo- α -ergocryptine; lack of effect on plasma aldosterone in anephric and non-nephrectomized patients on haemodialysis, 587
- prolactin inhibitors; effects on the ectopic adenohypophysis and on the mammary glands in rats, 267
- prolactin in male and female rats from birth to puberty, 718
- radioimmunoassay of canine prolactin, 736
- stimulation of prolactin secretion by sulphiride in "adolescent gynaecomastia", 692
- stress-induced prolactin release in rats, 729
- 6-PROPYLTHIOURACIL**
divergent effects on T_3 and RT_3 levels in man, 345
- PROSTATE**
carcinoma; sex hormone binding globulin, testosterone, 5 α -DHT, oestradiol and prolactin in plasma of patients under hormonal treatment, 650
- PROTEINS**
distribution of LATS in immunoglobulin G subclass, 791
glycoproteins in the skin of male mice: effect of oestradiol, 429
iodopeptides from human thyroglobulin, 769
lipoproteins in menopausal women: effect of piperazine oestrone sulphate, 143
lipotropic peptide B; radioimmunoassay, 291
C-peptides in diabetic and non-diabetic children, 364
serum thyroxine-binding globulin; determination in thyroid diseases and in pregnancy, 314
thyroxine-binding proteins; changes in serum levels induced by venous stasis, 39
- PUBERTY**
"adolescent gynaecomastia", 692
boys with irregular puberty; plasma LH and FSH response to LH-RH and plasma testosterone levels, 456
C-peptide and total immunoreactive insulin in diabetic and non-diabetic children, 364
precocious puberty induced by hypothalamic lesions in female rats; prolactin involvement, 11
prolactin, LH and FSH from birth to puberty in rats, 718
- RADIOIMMUNOASSAYS**
for canine prolactin, 736
for porcine lipotropic peptide B, 291
- RELEASING HORMONES**
LH-RH; decreased gonadotrophin response in infants with undescended testes, 644
LH-RH; effect during the first weeks of human pregnancy and during the menstrual cycle, 177
LH-RH; effect of LH-RH and steroids on release of LH and FSH from incubated turkey pituitary cells, 713
LH-RH; plasma LH and FSH responses in boys with irregular puberty, 456
LH-RH; responses of gonadotrophins to LH-RH in Japanese women with polycystic ovaries, 840
LH-RH; temporal changes during the rat oestrous cycle, 449
TRH; effect of prolonged administration on plasma TSH and prolactin in normal subjects and in hypothyroidism, 744
TRH; intravenous and peroral TRH stimulation in sporadic atoxic goitre; 508
TRH; prolactin responses in dogs, 736

- TRH; TSH response to TRH during treatment of patients with Graves' disease, 335
- TRH; TSH response to TRH in anorexia nervosa, 673
- TRH; TSH response to TRH in patients with hypophyseal disorders, 479
- RESERPINE**
effect on pro-oestrous LH surge in rats, 18
- RIFAMPICIN**
interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man, 189
- SECRETIN**
high plasma levels in diabetes mellitus, 799
- SELLA TURCICA**
spontaneous regression of enlargement of the sella and of associated pan-hypopituitary symptoms, 684
- SKELETON**
bone changes in hyperthyroidism; interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism, 515
- SKIN**
effect of oestradiol on hexosamine-containing substances and a possible receptor in the skin of male mice, 429
- SODIUM**
changes in sodium balance; effect on aldosterone excretion rate and plasma aldosterone in the rat, 134
correlation between serum sodium and serum prolactin concentration in diabetic ketoacidosis, 372
- SOMATOMEDIN**
somatomedin A and B in serum from neonates, their mothers and cord blood, 636
- SOMATOSTATIN**
effect of somatostatin analogues on arginine-induced release of insulin and glucagon from the perfused rat pancreas, 579
effect on insulin release and cyclic AMP in isolated rat Langerhans' islets, 379
inactivation by peptidases in hypothalamus and other areas of the rat brain, 1.
- SOMATOTROPHIN** *see* GROWTH HORMONE
- STRESS** *see* ADAPTATION SYNDROME
- SULPIRIDE**
stimulation of prolactin secretion by sulpiride in "adolescent gynaecomastia", 692
- TESTES**
cryptorchidism; pituitary LH and FSH and testosterone secretion, 644
- TESTOSTERONE**
assay of non-protein-bound testosterone by equilibrium dialysis, 209
effect on plasma and urinary uric acid in human subjects, 198
effect on release of LH and FSH from incubated turkey pituitary cells, 713
plasma concentration in patients with prostatic carcinoma under hormonal treatment, 650
plasma LH and FSH responses to plasma testosterone levels in boys with irregular puberty, 456
secretion in infants with undescended testes, 644
- THYMUS**
iodine uptake in rats of different ages, 64
- THYROGLOBULIN**
iodopeptides from human thyroglobulin, 769
long-term turnover of thyroid iodine in the rat as studied by the isotopic equilibrium method, 357

THYROID

- carcinogenesis (experimental) in rat thyroid follicular and C cells, 84
- diseases; studies on a case of suppurative thyroiditis, 55
- diseases; total and "activated" blood T lymphocytes, 753
- effect of amiodarone on thyroid iodine metabolism *in vitro*, 781
- endemic goitre in Alto Adige (Italy), 325
- function and plasma cyclic AMP response to intravenous glucagon, 760
- function in a case of suppurative thyroiditis, 55
- function in anorexia nervosa, 673
- Graves' disease; TSH response to TRH during treatment of the patients, 335
- hyperthyroidism; bone changes, 515
- iodine uptake in rats of different ages, 64
- primary hypothyroidism; effect of TRH on plasma TSH and prolactin, 744
- serum T₄-binding globulin; determination in thyroid disease and pregnancy, 314
- sporadic non-toxic goitre; a long-term follow-up of 36 patients, 497
- sporadic non-toxic goitre; intravenous and peroral TRH stimulation, 508
- thyroid iodine; long-term turnover as studied by the isotopic equilibrium method in the rat, 357
- thyroid tumour in rats; iodoamino acid distribution in successive tumour generations, 93
- T₄ and T₃ nuclear receptors in lymphocytes from normal, hyper- and hypothyroid subjects, 44

THYROIDITIS

- thyroid function in a case of suppurative thyroiditis, 55

THYROTROPHIN

- comparison of the effects of TSH, GH and prolactin on renal iodide excretion in unrestrained rabbits, 488

- effect on the tibial plate bioassay for growth hormone, 25
- high molecular thyrotrophin ("Big"-TSH) from human pituitaries; preparation and characterization, 698
- lack of acute effects on noradrenaline responses of isolated sympathectomized cat hearts, 220
- response to prolonged oral administration of TRH in normal subjects and in hypothyroidism, 744
- response to TRH in anorexia nervosa, 673
- response to TRH in sporadic atoxic goitre, 508
- secretion and biological activity in patients with hypophyseal disorders before and during TRH administration, 479
- stress-induced TSH release in rats, 729

THYROXINE

- effect on skeletal muscle metabolism in the rat, 71
- iodoamino acid distribution in successive thyroid tumour generations in rats, 93
- metabolism in the rat; *in vivo* studies, 351
- rapid disappearance of loading doses of T₄ from blood and their excretion by the bile in rats, 531
- serum levels of T₄ and T₄-binding proteins; changes induced by venous stasis, 39
- serum levels of T₄-binding globulin; determination by competitive ligand-binding assay, 314
- T₄ and T₃ binding interactions in cytosol fraction of rat pituitary cells, 256
- T₄ nuclear receptors in lymphocytes from normal, hyper- and hypothyroid subjects, 44

TRACE ELEMENTS

- in human endometrium and decidua, 406

TRIIODOTHYRONINE

- divergent effects of 6-propylthiouracil on T_3 and RT_3 serum levels in man, 345
- iodoamino acid distribution in successive thyroid tumour generations in rats, 93
- metabolism in the rat; *in vivo* studies, 351
- peripheral T_3 formation by oral but not by iv glucose administration in fasted subjects, 526
- T_3 nuclear receptors in lymphocytes from normal, hyper- and hypothyroid subjects, 44

TUMOURS

- experimental carcinogenesis in the rat thyroid follicular and C cells; effects of dietary Ca and radiation, 84
- functioning granulosa cell tumours; demonstration of an FSH receptor, 615
- hypophyseal tumours; effects of thyrotrophin releasing hormone, 479

- parathyroid tumours; effects of Ca and dibutyryl cyclic AMP on secretion of parathyroid hormone by human parathyroid adenomas in organ culture, 541
- prostatic carcinoma; endocrine studies in relation to hormonal therapy, 650
- transplantable thyroid tumour in rats; iodoamino acid distribution in successive tumour generations, 93

URIC ACID

- plasma and urine levels in human subjects; relationship to sex steroids, 198

UTERUS

- rat endometrium enzymes in 4-day oestrous cycle and early pregnancy, 169
- trace elements in the human endometrium and decidua, 406

VIRILIZATION

- aberrant 11β -hydroxylation in a case of adrenogenital syndrome, 832

Laboratories for Clinical Chemistry and Endocrinology,
II. Medical Clinic, University of Munich.
Munich, FRG

HIGH MOLECULAR THYROTROPHIN ("BIG"-TSH)
FROM HUMAN PITUITARIES: PREPARATION AND PARTIAL
CHARACTERIZATION

By

Friedrich W. Erhardt and Peter C. Scriba

A B S T R A C T

Homogenates of human pituitaries were centrifuged at $30\,000 \times g$ and the supernatant chromatographed on Sephadex G-100. Approximately 1% of the radioimmunologically measured total activity of TSH was eluted in the void volume. Rechromatography of this material on Sephadex G-200 usually showed TSH-activity at $K_{av} = 0.5$ (regular TSH), $K_{av} = 0$ (void volume-TSH) and at $K_{av} = 0.3$ ("big"-TSH). "Big"-TSH was extracted from the corresponding fractions by affinity-chromatography with solid phase anti-TSH. It was eluted with 5 mol/l ammonium thiocyanate and further characterized:

1. The molecular weight was approximately 200 000 by comparison with bovine catalase on Sephadex G-200.
2. Immunoidentity as compared with standard-TSH (M. R. C. 68/38) was shown by parallel dilution curves in the radioimmunoassay.
3. Concanavalin-A-Sepharose adsorbed "big"-TSH, which could be eluted with α -methyl-D-mannoside, indicating the glycoprotein nature of "big"-TSH.
4. On polyacrylamide-gel-electrophoresis pH 7.5, "big"-TSH migrated faster ($R_f = 0.32$) than regular TSH ($R_f = 0.1$), indicating a more negatively charged molecule.
5. "Big"-TSH, in contrast to regular TSH, was remarkably stable against 6 mol/l guanidine hydrochloride, suggesting a covalently linked (aggregate) structure.

6. 1% mercaptoethanol destroyed the immunological activity of both regular and "big"-TSH.
7. "Big"-TSH was digested by trypsin, under mild conditions, to radio-immunologically active products with molecular weights between "big"- and regular TSH, but practically no regular TSH was formed.
8. "Big"-TSH and guanidine-treated "big"-TSH, as well as regular TSH and TSH from the void volume of Sephadex G-200 columns, exhibited biological activity in a cytochemical bioassay in good agreement with the respective immunological activities.

High molecular forms of proteohormones known as "big"-hormones have been described for several years as reviewed by *Yalow* (1974). Recently, "big"-hormones were also observed in the field of pituitary glycoprotein hormones: "big"-LH (*Prentice & Ryan* 1975; *Graesslin et al.* 1976) "big"-TSH (*Erhardt* 1975; *Erhardt & Scriba* 1976) and "big"- β -TSH (*Golstein-Golaire & Vanhaelst* 1975; *Kourides et al.* 1976). There is still little known about the chemical structure and biological significance of the high molecular species of glycoprotein hormones.

MATERIALS AND METHODS

Reagents

Rabbit IgG for coprecipitation in the radioimmunoassays; bovine catalase, equine ferritin for the calibration of Sephadex columns; materials for polyacrylamide-gel-electrophoresis (PAGE): Acrylamide, tetramethylethylenediamine, N,N-methylenebisacrylamide and ammonium persulphate; Triton X 100; α -methyl-D-mannoside; trypsin (less than 0.24% chymotrypsin) and trypsin inhibitor from lima bean were obtained from Serva GmbH (Heidelberg, Germany).

All Sephadex gels (G-75; G-100; G-200; QAE-A-50; Cl-Sepharose 2 B; Con A-Sepharose) were obtained from Pharmacia Fine Chemicals (Uppsala, Sweden), and sodium phosphate, sodium chloride, sodium EDTA, sodium azide, ammonium thiocyanate, and guanidine (mostly analytical grade), from Merck AG (Darmstadt, Germany). Bovine albumin (Pentex®) was purchased from Roth (Munich, Germany). TSH for labelling and anti-TSH for radioimmunoassay were kindly donated by the NIAMDD (Bethesda, Maryland). Anti-TSH for affinity-chromatography was donated by Farbwerke Hoechst AG (Frankfurt, Germany). Sodium ¹²⁵Iodide for labelling was also obtained from Hoechst AG. Anti-TSH-serum for affinity chromatography was also produced in our laboratories by immunization of two rabbits with TSH (4 U/mg) purchased from Deutsche Kabi GmbH (Munich, Germany). HCG, Primogonyl® for absorption in the radioimmunoassay of TSH and for immunization of rabbits, was obtained from Schering AG (W-Berlin, Germany). Anti-rabbit precipitating serum (donkey) was obtained from Wellcome Ltd. (England). "Eppendorf" plastic tubes (vol. 1.5 ml) for all radioimmunoassays were purchased from Netheler & Hinz (Hamburg, Germany). Human pituitaries obtained at autopsy, usually performed 24–36 h after exitus, were kept frozen at -28°C. Pituitaries kept in acetone were also used.

Buffers

- A: 0.015 mol/l sodium phosphate; 0.15 mol/l sodium chloride; 0.2 % bovine-albumin; 0.002 % sodium azide; 0.02 mol/l EDTA, pH 7.4.
B: As buffer A, with 4.2 % bovine albumin and no EDTA.
C: As buffer A, but without albumin and EDTA.
D: 0.1 mol/l sodium phosphate, pH 6.5.
E: 0.5 ml/l sodium carbonate, pH 8.6.
F: As buffer E, but with 2 mol/l sodium chloride, pH 8.6.
G: 0.1 mol/l sodium carbonate; 2 mol/l sodium chloride, pH 8.6.
H: 0.1 mol/l sodium acetate; 2 mol/l sodium chloride, pH 4.5.
I: 0.01 mol/l Tris, pH 7.5.

Radioimmunoassays of hTSH, hLH and hGH

Radioimmunoassays were carried out using the double antibody technique and a modular analyzer system (Marschner *et al.* 1975), RIA-E-6000 labororium Prof. Berthold (Karlsruhe, Germany) and Ismatec (Zürich, Switzerland). All hormones were labelled with ^{125}I by slight modification of the chloramine-T-method (Greenwood *et al.* 1963). HTSH was measured with minor modifications as described previously (Erhardt *et al.* 1973) using the international standard M. R. C. 68/38 (NIMR, Mill Hill, London). HLH was measured using anti-HCG from rabbits from our laboratory, LH for labelling was purchased from Calbiochem (California, USA), and standard L. E. R. 907 obtained from NIAMDD. HGH was measured using rabbit anti-HGH from our laboratory, HGH "reinst" for labelling and "creschormone" for standards from Deutsche Kabi GmbH (Munich, Germany).

Preparation of "big"-TSH

4–50 pituitaries were thawed at 4°C and homogenized in 5–30 ml cold buffer C for 1 min in a Vortex homogenizer at low speed and for 1 min at high speed. The temperature was allowed to rise to 27°C. The homogenate was centrifuged for 30 min at $30\,000 \times g$ at 4°C in a Beckmann ultracentrifuge type L-40. The red-brown and still turbid supernatant was chromatographed on a Sephex G-100 glass column (3 × 130 cm) with buffer C under hydrostatic pressure (flow rate 10–15 ml/h). Fractions from 3–6 ml were collected in glass tubes using fraction collector Linear II, Serva GmbH (Heidelberg, Germany). The hormone activities, TSH, LH and HGH were measured in each fraction in adequate dilutions (10^0 – 10^5) in buffer B. Crude "big"-TSH was eluted constantly in the turbid fractions of the void volume ($K_{av} = 0$) and was usually measured in 1 to 100 μl of the eluates (Fig. 1).

For further purification the "big"-TSH containing fractions were concentrated to a volume of 2–5 ml by ultrafiltration at 4°C, using collodion bags, obtained by Sartorius AG (Göttingen, Germany).

After centrifugation at $30\,000 \times g$ for 30 min, the turbid concentrate was re-chromatographed on Sephadex G-200 under hydrostatic pressure. The columns were previously coated with 20 ml buffer B and were equilibrated over-night at 4°C with elution buffer C; 3–6 ml fractions were collected (Fig. 2).

Immunization of rabbits

TSH-antiserum was raised in 2 rabbits, which were each immunized by 4 injections, beginning with 100 μg subcutaneously followed by 3 injections of 50 μg TSH, all in incomplete Freund's adjuvant. After eight weeks one rabbit showed 50 % binding of [^{125}I]TSH in a final dilution of 1:100 000.

Preparation of the anti-TSH-affinity gel

Activation of Cl-Sepharose-2 B by cyanogen bromide purchased from Merck AG (Darmstadt, Germany) was performed according to the instructions of Pharmacia Fine Chemicals. Ten g of the wet gel cake was suspended in 30 ml buffer E and reacted with 4 g cyanogen bromide, dissolved in 20 ml of distilled water. Under continuous control by a glass-electrode and under magnetic stirring, the pH of the mixture was kept between pH 10 and 11 by dropwise addition of 20 % sodium hydroxide. The temperature was kept below 30°C by addition of ice. After 20 min the reaction mixture was filtered through a sintered glass funnel and washed with 500 ml of 0.1 mol/l sodium carbonate, pH 8.6.

Binding of anti-TSH-IgG

The preparation of IgG was performed using the ion exchange gel QAE-A-50-Sepharose according to the instructions of Pharmacia Fine Chemicals, elution was with buffer D, and concentration by ultrafiltration. Five mg of the IgG dissolved in 10 ml buffer F was added to 1 g of the wet, freshly prepared activated Cl-Sepharose-2 B-cake in a polystyrene-beaker and slowly rotated at room temperature for 3 h continued over-night at 4°C. The mixture was again filtered over a sintered glass funnel. The optical density of the filtrate at 280 nm was measured and compared with the light absorption before extraction with the activated gel to calculate roughly the proportion of protein linked to the gel. This varied between 40–90 % (2–4.5 mg protein/g wet Sepharose).

To inactivate the anti-TSH gel it was suspended in 20 ml of 1 mol/l glycine and rotated for 3 h at room temperature. After filtration, the affinity gel was repeatedly and alternately washed 10 times with buffer G and buffer H (50 ml each).




Fig. 1.

Chromatogram of the 30 000 g supernatant of 4 human pituitaries on Sephadex G-100 (134 × 3 cm; buffer C; 4°C).




Fig. 2.

Chromatograms of "big"-TSH on Sephadex G-200 before and after mild tryptic digestion. (130 × 1.7 cm; buffer C; 4°C).

- Crude product from Sephadex G-100, showing void volume TSH (I); "big"-TSH (II) and regular TSH (III).
- Untreated "big"-TSH, re-chromatographed.
- 5 min treated with trypsin.
- ▲— 10 min treated with trypsin.

Specific extraction of "big"-TSH from Sephadex eluates

One g of wet, freshly prepared affinity-gel was added to the pooled "big"-TSH fractions from the Sephadex chromatography (20–80 ml). After slow rotation at room temperature for 2 h the gel was filtered (Schott AG, Fritte 1 G 2) and again repeatedly washed (at least 4 times), alternating between buffer G and buffer H in order to remove physically adsorbed proteins.

Elution of "big"-TSH from the affinity-gel

The wet affinity-gel cake loaded with "big"-TSH was suspended in buffer C and poured into a small column (10 ml plastic syringe with filter). "Big"-TSH was eluted with 20 ml of freshly prepared 5 mol/l ammonium thiocyanate in distilled water, pH 7, within 10–20 min and collected in dialysis tubing. Dialysis against 6 l distilled water was carried out over 24 h at 4°C with a single change of the outer fluid. The dialyzed "big"-TSH was subsequently concentrated by ultrafiltration through collodion bags to give a final volume of 0.5–1 ml. HTSH, HGH and HLH activity were determined by radioimmunoassay and the protein concentration by lightabsorption at 280 nm ($0.7 \text{ O. D.}_{280} \cong 1 \text{ mg protein/ml}$) to monitor the purification. The product was re-chromatographed on Sephadex G-200 and the fractions collected either in siliconized glass

tubes, or with 0.2 ml of buffer B in the bottom of the tubes, in order to reduce adsorption onto the glass. Concentration was again performed by ultrafiltration in collodion bags.

Polyacrylamide-gel-electrophoresis (PAGE)

PAGE was performed in 0.5 mol/l Tris-HCl at p H7.5 (Smith 1968). Bromphenolblue was used as a marker. Two hundred μ U of "big"-TSH or TSH, respectively, was applied to the columns (separation gel: 7×0.5 cm, concentration gel 2×0.5 cm). At the end of the electrophoresis, the gels were frozen at -80°C for 30 min and subsequently cut into 45 slices of 1.5 mm using razor-blades. The slices were each placed in 0.6 ml of buffer B and allowed to elute (for 20 h) at room temperature. The TSH-activity in the eluate from each slice was measured by radioimmunoassay (Fig. 5).

Treatment of "big"-TSH and regular TSH with guanidine and Triton X 100

Triton X 100 (0.25 %) and guanidine-HCl (6 mol/l final concentration) were dissolved in 2 ml of "big"-TSH-solution in buffer A (pH 5.1), and the mixture incubated for 1 h at 37°C . For comparison, incubations were also performed without guanidine, but with Triton X 100, and without both. The reaction mixtures were chromatographed on Sephadex G-100 or G-200, respectively (Fig. 6).

Mild tryptic digestion of "big"-TSH

Twenty μg of trypsin in 20 μl buffer C was added to 160 μU of "big"-TSH from Sephadex G-200 in 200 μl of buffer C in a small siliconized glass tube. No calcium was added. The solution was incubated at 37°C for 5 or 10 min, respectively, after which 10 μg of lima bean inhibitor in 20 μl buffer C was added in order to stop the reaction. Re-chromatography was performed on 130×1.7 cm Sephadex G-200, as for the undigested "big"-TSH (Fig. 2).




Fig. 3.

Comparison of the radioimmunologically and cytochemically measured TSH-activity of human pituitary TSH-fractions from Sephadex G-200 and of "big"-TSH after treatment with 6 mol/l guanidine-HCl and desalting by re-chromatography.




Fig. 4.

Dilution curve of "big"-TSH from affinity chromatography after re-chromatography on Sephadex G-200, compared with TSH-standard M. R. C. 68/38.

—●— Dilutions of "big"-TSH.
 — Standard curve.

Mercaptoethanol treatment of "big"-TSH

Ten μ l mercaptoethanol was added to 160 μ U "big"-TSH in 1 ml buffer B. For comparison, M. R. C. 68/38-TSH was treated identically. After 50 h at 4°C and after 1 h at 37°C, aliquots of the reaction mixtures were diluted 1:10 with buffer B to eliminate unspecific effects of mercaptoethanol. TSH-activity was then measured by radio-immunoassay and compared with the activity before treatment. The "big"-TSH was re-chromatographed on 1.1 \times 70 cm Sephadex G-100 (Fig. 7).

Adsorption of "big"-TSH to Con A-Sepharose

Two ml of Con A-Sepharose was applied to a 5 ml plastic syringe fitted with a glassfilter, and 80 μ U of "big"-TSH was added in 0.1 ml of buffer C. The column was washed with 8 ml buffer C and the elution subsequently performed with 10 ml 0.05 mol/l α -methyl-D-mannoside in buffer C. One ml fractions were collected into Eppendorf vials containing 50 μ l of buffer B.

Determination of the DNA-content of "big"-TSH

Ten mU of "big"-TSH (enriched by affinity chromatography and equivalent to approximately 3 μ g of regular TSH), dissolved in 0.1 ml of buffer A was treated with 10 μ l (1 mg/ml) proteinase K (Merck AG, Darmstadt, Germany), after dilution with 0.4 ml buffer I, for 17 h at 37°C, to liberate RNA and DNA from the protein moiety

of "big"-TSH. The measurement of DNA and RNA was performed using the sensitive fluorescence method with ethidium bromide in the presence of 0.07 mol/l magnesium chloride (Paoletti & Le Pecq 1971), and a Perkin-Elmer fluorescence spectrometer (MPF-2A). The fluorescence emission was monitored at 586 nm after calibration with calf thymus DNA and with unfractionated yeast t-RNA (Boehringer, Mannheim, Germany). The limit of detection for DNA was approximately 0.1 $\mu\text{g/ml}$ and for t-RNA 1 $\mu\text{g/ml}$.

Measurement of the biological activity

The measurement of the biological activity was performed in the laboratory of Dr. von zur Mühlen, Hannover, using the cytochemical bioassay (Bitensky *et al.* 1974). The biological activity was measured in the three main fractions ($K_{av} = 0, 0.3$ and 0.5) of pituitary-TSH chromatographed on Sephadex G-200 and likewise in a guanidine-treated and re-chromatographed "big"-TSH fraction. M. R. C.-TSH-standard A was used for calibration. TSH activities of the same fractions were determined in our laboratory in Munich by radioimmunoassay using M. R. C. 68/38 as standard. Comparison of standard A and 68/38 in the radioimmunoassay showed standard A to have $85 \pm 7\%$ of the activity of 68/38-TSH (Fig. 3).

RESULTS

Chromatography of pituitary supernatants

Chromatograms of the $30\,000 \times g$ supernatants from human pituitary homogenates on Sephadex G-100 columns always showed turbid fractions eluting in the void volume with TSH-activities of about 1% of the total TSH-activity (Fig. 1). However, re-chromatography on Sephadex G-200 showed that these fractions from G-100 were not homogeneous, but were separated into TSH-fractions eluting in the void volume of G-200 ($K_{av} = 0$), "big"-TSH-fractions of $K_{av} 0.3$ and regular TSH ($K_{av} = 0.5$) (Figs. 2 and 3). The amount of TSH found in the void volume was dependent on the gravity force during centrifugation, indicating that in these fractions TSH was still linked to pituitary cell fragments. The further experiments were mainly performed with "big"-TSH ($K_{av} = 0.3$).

Characterization of "big"-TSH

"Big"-TSH, purified only by re-chromatography on Sephadex G-200 or further purified by affinity chromatography, displayed parallelism of its dilution curves to TSH-standards in the radioimmunoassay (Fig. 4). It was eluted on a calibrated Sephadex G-200 column shortly behind bovine catalase (M. W. 240 000), pointing to a molecular weight of approximately 200 000. The same product chromatographed in the polyacrylamide-gel-electrophoresis in Tris-buffer pH 7.5 migrated with a $R_F = 0.32$ significantly faster than regular TSH ($R_F = 0.1$), indicating "big"-TSH to be a more negatively charged mole-




Fig. 5.

Polyacrylamid-gel-electrophoresis of TSH and "big"-TSH.

A —○— Regular TSH (NIAMDD HTSH for labelling).

B —●— "big"-TSH.

Gel: 7 × 0.5 cm; 0.5 M Tris, pH 7.5; 5–3 mA/column.

The TSH-activity was measured by radioimmunoassay in 1.5 mm slices after elution with buffer B (0.6 ml/slice).

cule (Fig. 5). Affinity chromatography of "big"-TSH on Con A-Sepharose showed that it behaves like a glycoprotein, since it was bound to Con A-Sepharose like regular TSH. It could also be displaced and eluted by α -methyl-D-mannoside.

Measurements of the DNA and RNA content of "big"-TSH, after enrichment by affinity chromatography, using the very sensitive fluorescence method with ethidium bromide displayed DNA and RNA content below the limit of detection: less than 1.5 % DNA and less than 15 % RNA.

All TSH-fractions (Fig. 3), including those treated with guanidine, displayed biological activity. The biological activity of the trypsin-treated fractions have not been measured, because no well defined products were formed.

Purification and yield of "big"-TSH after preparation by affinity chromatography

Affinity chromatography with solid phase anti-TSH after prior separation of a well defined "big"-TSH fraction by Sephadex chromatography, resulted in a 15–40-fold purification as compared with protein or HGH, respectively,

Table 1.

Purification and yield of "big"-TSH from 50 pituitaries by affinity chromatography with anti-TSH-Sepharose and Con A-Sepharose after prior separation from regular TSH and void volume TSH by one chromatography run on Sephadex G 100 and two subsequent runs on Sephadex G 200 (results of one experiment).

	Absolute amounts				Purification			Yield "Big"-TSH (%)
	"Big"-TSH (mU)	HLH (U)	HGH (μ g)	Protein (mg)	TSH/HLH (mU/U)	TSH-HGH (mU/ μ g)	TSH/protein (mU/mg)	
Before affinity chromatography	18	47	380	19	0.38	0.047	0.95	100
In the ammonium thiocyanate eluate after extraction by anti-TSH-Sepharose	3.1	2.8	4.1	0.18	1.1	0.76	17.2	16.7
In the α -methyl-D-mannoside eluate after extraction by 1 ml Con A-Sepharose	0.5	0.8	0.12	not measurable (< 0.05)	0.6	4.2	> 10	2.8




Fig. 6.

Chromatograms of crude "big"-TSH on Sephadex G-100 after various treatments. (127 × 1.7 cm; buffer C; 4°C).

- 1) ···○··· Untreated.
- 2) —□— 1 h; 37°C; 0.25 % Triton X 100; pH 7.4.
- 3) —●— 1 h; 37°C; 0.25 % Triton X 100; 6 mol/l guanidine-HCl; pH 5.1.

The first peak represents "big"-TSH, the second peak regular TSH, the third peak, only seen on the guanidine-treated material, has not fully been investigated, but possibly contains β -TSH, which shows almost the same binding characteristics with the antibody as the TSH-standard used in the assay.

and 2–10-fold when compared with HLH. In this step the yield of "big"-TSH dropped from 100 to between 15 and 30 %.

Further purification was achieved on Con A-Sepharose, the protein concentration then being below the limit of detection ($< 50 \mu\text{g}$ protein/ml). As compared with HGH this procedure resulted in a further 5–10-fold purification. However, compared to HLH no further purification was achieved. The yield of "big"-TSH dropped by an additional factor of about 5.

Table 1 shows the results of one experiment, where the purification of "big"-TSH was approximately 100-fold as compared to somatotrophin.

Stability of "big"-TSH

In an attempt to convert "big"-TSH to regular TSH and to find some indications concerning the structure of "big"-TSH, the product was treated with 6 mol/l guanidine, 1 % mercaptoethanol and trypsin, respectively.

Treatment with 6 mol/l guanidine for 1 h at 37°C in the presence of 0.25 %




Fig. 7.

Chromatograms of TSH and "big"-TSH on Sephadex G-100 after treatment with mercaptoethanol. (70×1.1 cm; buffer C; 4°C).

- HTSH (M. R. C. 68/38) untreated.
- "big"-TSH untreated.
- "big"-TSH in buffer B; 1 h; 37°C ; 1 % mercaptoethanol, pH 7.4.
- "big"-TSH 66 h; 4°C ; 1 % mercaptoethanol, pH 7.4.

of the detergent Triton X 100 at pH 5.1 resulted in only a minor degradation of about 10–15 % in contrast to regular TSH, which was almost completely destroyed under the same conditions (Fig. 6). Triton X 100 alone had no significant effect on "big"-TSH. Moreover, the guanidine-treated "big"-TSH did not lose its biological activity, as shown in the cytochemical bioassay (Fig. 3).

Treatment with 1 % mercaptoethanol at 4°C and at 37°C led to loss of the immunological activity of "big"-TSH and regular TSH at similar rates, so that an intermediate formation of regular TSH from "big"-TSH could not conclusively be shown by this experiment. At 37°C , both "big"-TSH and regular TSH lost 90 % of their immunological activities in the radioimmunoassay. At 4°C , approximately 50 % was lost within 48 h. Re-chromatography of the mercaptoethanol-treated "big"-TSH showed only a minor peak in the region where regular TSH would be expected (Fig. 7).

The digestion experiments with trypsin were performed in a mild procedure at pH 7.4 in the absence of calcium. Re-chromatography of the digestion mixture on Sephadex G-200 demonstrated the formation of still immunologically active cleavage products, which were eluted between "big"-TSH and regular TSH, indicating molecular weights between "big"- and "regular" TSH. There was practically no products formed which could be eluted in the volume where TSH should appear (Fig. 2).

So far none of the cleavage experiments have succeeded in the formation of regular TSH from "big"-TSH.

DISCUSSION

High-molecular forms of HTSH have not been observed earlier probably because of the minute amounts found in the supernatant of pituitary homogenates, and because of the necessity of using long columns to separate "big" from regular TSH. Additionally, the "big"-TSH-fractions obtained after chromatography on Sephadex G-100 columns are not homogeneous. On Sephadex G-200, turbid fractions can again be obtained, in which TSH is probably still linked to cell-fragments ("void volume-TSH"). The second fraction, which was eluted on G-200 between the void volume TSH and regular TSH, differs mainly in three aspects from regular TSH:

Firstly, it showed a molecular weight of about 7 times that of regular TSH by chromatographic comparison with bovine catalase, secondly, in contrast to regular TSH, "big"-TSH was not cleaved into subunits by 6 mol/l guanidine, and finally, it migrated faster on PAGE pH 7.5 when compared with highly purified TSH in spite of its much bigger molecular weight.

This indicates more negatively charged groups, which could for instance be sialic acid groups. As tested by fluorescence with the ethidium bromide method, "big"-TSH contains no DNA or RNA in significant amounts.

However, "big"-TSH also displays a series of features very similar to regular TSH which do not exclude a relationship to regular TSH. Firstly it showed parallelism of its dilutions when compared with standard TSH in the radioimmunoassay, indicating identity of the antigenic sites and good accessibility for the specific antibody, so that the antigenic site does not seem to be folded into the big protein. Moreover, "big"-TSH was bound to Con A-Sepharose like glycoproteins just as regular TSH and could be displaced readily by α -methyl-D-mannoside. These features make it very likely that "big"-TSH contains, in some still unknown manner, regular TSH. The high stability against 6 mol/l guanidine is surprising, but is in accordance with the high stability of "big"-LH as described by *Prentice & Ryan* (1975). This suggests, that "big"-TSH is not a mere aggregate but a covalently linked product, and indicates in addition, that the subunits in this "big"-TSH may also

be covalently linked, in contrast to those of regular TSH, which are easily cleaved by 6 mol/l guanidine.

We still do not know, if "big"-TSH is a product, in which regular TSH is linked to a second "big"-protein or whether "big"-TSH is a covalently linked polymer of regular TSH. The latter possibility could be clarified, when sufficient amount of purified "big"-TSH has been prepared for the determination of its specific activity. Our attempts to cleave "big"-TSH with mercaptoethanol showed only, that the immunological activity was destroyed in the same way as that of regular TSH under these conditions. From these experiments, we are therefore not able to elucidate on the combining groups in the "big"-TSH. But at the same time we cannot exclude, that disulphide groups play a role in binding.

Our attempts to cleave "big"-TSH by tryptic digestion did not result in the production of regular TSH. This is in contrast to "big"-ACTH, which is transformed to regular ACTH by trypsin as described by *Yalow* (1974). But at least tryptic digestion products were formed, which still showed immunological activity in the radioimmunoassay and which on re-chromatography on Sephadex G-200 displayed molecular weights between "big"-TSH and regular TSH.

Interestingly, regular TSH, as well as "big"-TSH, guanidine-treated "big"-TSH and void volume TSH, showed biological activity in the cytochemical bioassay in good agreement with the radioimmunological findings. This allows the suggestion that in "big"-TSH as in void volume TSH the immunologically/biologically active sites are accessible to the TSH-receptors of thyroid cells.

The question of the amount of alpha and beta subunits in the "big"-TSH molecule can only be answered when firstly, "big"-TSH has been further purified, mainly using affinity chromatographic techniques with Con A-Sepharose and solid-phase-anti-TSH, and secondly, when a mild cleavage procedure has been found. Attempts to determine the amount of alpha and beta subunits included in the "big"-TSH, based on measurements in poorly purified Sephadex eluates, are not valid because of the cross-reaction of the accompanying glycoproteohormones and their subunits which complicate the quantitation.

In a few experiments, where serum of hypothyroid patients was chromatographed on Sephadex G-100 or 200 no TSH-activity was found at the position, where "big"-TSH should appear, even with a very sensitive radioimmunoassay (limit of detection 0.1 μ U/ml). Interestingly *Golstein-Golairé & Vanhaelst* (1975) and *Kourides et al.* (1976) reported beta-TSH-subunit-activity in some hypothyroid sera, corresponding to a "big"-beta-TSH with a molecular weight of approximately 160 000. It is still not known whether there is any relationship between the "big"-beta-TSH found occasionally in serum and "big"-TSH regularly present in pituitaries.

The physiological significance of "big"-TSH is still obscure and open to speculation. Up to date, it cannot be excluded that "big"-TSH is merely a side-product or an oxidation product of no physiological importance. If "big"-TSH has any physiological significance, then we rather believe, because of the minute amounts present, that it is an intermediate between an even larger precursor and regular TSH, rather than a storage form, as has been suggested by *Golstein-Golaire & Vanhaelst* (1976). The "intermediate" hypothesis can, however, only be proven when we succeed in showing the formation and the disappearance of "big"-TSH in pituitary cells.

ACKNOWLEDGMENTS

We are indebted to Dr. K. Döhler and Prof. Dr. A. von zur Mühlen, Hannover, for the TSH-measurements in the cytochemical bioassay. We are also grateful to Miss C. Schuster for her technical assistance, Miss B. Glöckner and Miss R. Rothenfusser for HLH- and HGH-measurements, Dr. W. Kerner for the performance of the polyacrylamide-gel-electrophoresis and Dr. M. Kahan and Dr. R. E. Streek for their help in fluorescence measurements of RNA and DNA. This work was supported by the Deutsche Forschungsgemeinschaft SFB 51, Munich.

REFERENCES

- Bitensky L., Alagband-Zadeh J. & Chayen J.*: Clin. Endocr. 3 (1974) 363.
Erhardt F. W.: Acta endocr. (Kbh.) Suppl. 193 (1975) 3.
Erhardt F. W., Marschner I., Pickardt C. R. & Scriba P. C.: Z. klin. Chem. 11 (1973) 381.
Erhardt F. W. & Scriba P. C.: V. Internat. Congr. Endocr., Hamburg (1976). Abstract No. 332.
Golstein-Golaire J. & Vanhaelst L.: J. clin. Endocr. 41 (1975) 575.
Golstein-Golaire J. & Vanhaelst L.: VII. Annual Meeting of the European Thyroid Assoc. Helsinki 1976. Acta endocr. (Kbh.) Suppl. 204 (1976) Abstract No. 4.
Graesslin D., Leidenberger F., Glismann D., Lichtenberg V. & Czygan P.: V. Internat. Congr. Endocr., Hamburg (1976). Abstract No. 324.
Greenwood F. C., Hunter W. M. & Glover J.: Biochem. J. 89 (1963) 114.
Kourides J. A., Weintraub B. D. & Maloof F.: V. Internat. Congr. Endocr., Hamburg (1976) Abstract No. 333.
Marschner I., Erhardt F. W., Henner J. & Scriba P. C.: Z. klin. Chem. 13 (1975) 481.
Paoletti J. & Le Pecq J.-B.: J. molec. Biol. 59 (1971) 43.
Prentice G. & Ryan R.: J. clin. Endocr. 40 (1975) 303.
Smith I.: Chromatographic and Electrophoretic Techniques, Vol. II. William Heinemann Ltd., London (1968).
Yalow R. S.: Recent Progr. Hormone Res. 30 (1974) 597.

Received on October 18th, 1976.